Literature DB >> 24456846

Elevated C-reactive protein levels may be a predictor of persistent unfavourable symptoms in patients with mild traumatic brain injury: a preliminary study.

Shao-Hua Su1, Wei Xu2, Ming Li3, Lin Zhang4, Yi-Fang Wu5, Fei Yu5, Jian Hai6.   

Abstract

The pathogenesis of persistent unfavourable outcomes following mild traumatic brain injury (mTBI) are not fully understood. Low-grade systemic inflammation might contribute to the development of persistent unfavourable outcomes in patients with mTBI. We used plasma high-sensitivity C-reactive protein (CRP) levels as the biomarker of systemic inflammation to investigate whether elevated CRP levels were associated with persistent adverse outcomes in these patients. A total of 213 consecutive patients with mTBI were identified in our study. Plasma high-sensitivity CRP levels were measured at baseline, 1month, 2months and 3months after initial traumatic brain injury. The study endpoints included persistent postconcussion syndrome (PCS), persistent psychological problems (depression and anxiety), persistent physiological problems (frequent headache, nausea, insomnia, dizziness and fatigue) and persistent cognitive impairment, which were screened by International Classification of Diseases (ICD-10), diagnostic and statistical manual of mental disorders (DSM-IV), Beck anxiety inventory (BAI), Beck depression inventory (BDI) and montreal cognitive assessment (MoCA) 3months post-injury. The associations between baseline CRP levels and persistent unfavourable outcomes were estimated from multiple regression models adjusting for various confounding covariates. Elevated baseline CRP levels were associated with a significant increase in the incidence of persistent PCS (odds ratio [OR], 2.719; 95% confidence interval [CI], 1.609-4.594; p=0.000), persistent psychological problems (OR, 1.535; 95% CI, 1.063-2.216; p=0.022), and persistent cognitive impairment (OR, 1.687; 95% CI, 1.135-2.507; p=0.010). However, elevated CRP levels were not associated with persistent physiological problems (OR, 1.330; 95% CI, 0.905-1.956; p=0.146). Furthermore, three adjusted models did not essentially affect the OR of elevated CRP levels for these persistent unfavourable outcomes. Among patients with mTBI, baseline elevated CRP levels may be an independent predictor of persistent persistent PCS, psychological problems and cognitive impairment.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Cognitive impairment; Depression; High-sensitivity C-reactive protein; Mild traumatic brain injury; Postconcussion syndrome

Mesh:

Substances:

Year:  2014        PMID: 24456846     DOI: 10.1016/j.bbi.2014.01.009

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  24 in total

1.  Systemic inflammation moderates the association of prior concussion with hippocampal volume and episodic memory in high school and collegiate athletes.

Authors:  Benjamin L Brett; Jonathan Savitz; Morgan Nitta; Lezlie España; T Kent Teague; Lindsay D Nelson; Michael A McCrea; Timothy B Meier
Journal:  Brain Behav Immun       Date:  2020-07-24       Impact factor: 7.217

2.  Acute elevation of serum inflammatory markers predicts symptom recovery after concussion.

Authors:  Morgan E Nitta; Jonathan Savitz; Lindsay D Nelson; T Kent Teague; James B Hoelzle; Michael A McCrea; Timothy B Meier
Journal:  Neurology       Date:  2019-07-03       Impact factor: 9.910

3.  Potential of Hematologic Parameters in Predicting Mortality of Patients with Traumatic Brain Injury.

Authors:  Sol Bi Kim; Youngjoon Park; Ju Won Ahn; Jeongmin Sim; Jeongman Park; Yu Jin Kim; So Jung Hwang; Kyoung Su Sung; Jaejoon Lim
Journal:  J Clin Med       Date:  2022-06-05       Impact factor: 4.964

4.  Prediction of in-hospital mortality and morbidity using high-sensitivity C-reactive protein after burr hole craniostomy.

Authors:  Jung Ju Choi; Hong Soon Kim; Kyung Cheon Lee; Hojin Hur; Youn Yi Jo
Journal:  J Anesth       Date:  2016-10-07       Impact factor: 2.078

5.  A Prospective Study of Acute Blood-Based Biomarkers for Sport-Related Concussion.

Authors:  Timothy B Meier; Daniel L Huber; Luisa Bohorquez-Montoya; Morgan E Nitta; Jonathan Savitz; T Kent Teague; Jeffrey J Bazarian; Ronald L Hayes; Lindsay D Nelson; Michael A McCrea
Journal:  Ann Neurol       Date:  2020-04-20       Impact factor: 10.422

6.  Alterations in Plasma microRNA and Protein Levels in War Veterans with Chronic Mild Traumatic Brain Injury.

Authors:  Vikas Ghai; Shannon Fallen; David Baxter; Kelsey Scherler; Taek-Kyun Kim; Yong Zhou; James S Meabon; Aric F Logsdon; William A Banks; Abigail G Schindler; David G Cook; Elaine R Peskind; Inyoul Lee; Kai Wang
Journal:  J Neurotrauma       Date:  2020-03-11       Impact factor: 5.269

7.  The relationship between salivary C-reactive protein and cognitive function in children aged 11-14years: Does psychopathology have a moderating effect?

Authors:  Alexis E Cullen; Ben M Tappin; Patricia A Zunszain; Hannah Dickson; Ruth E Roberts; Naghmeh Nikkheslat; Mizan Khondoker; Carmine M Pariante; Helen L Fisher; Kristin R Laurens
Journal:  Brain Behav Immun       Date:  2017-07-08       Impact factor: 7.217

Review 8.  Mild Traumatic Brain Injury (mTBI) and chronic cognitive impairment: A scoping review.

Authors:  Kerry McInnes; Christopher L Friesen; Diane E MacKenzie; David A Westwood; Shaun G Boe
Journal:  PLoS One       Date:  2017-04-11       Impact factor: 3.240

9.  Rhamnetin attenuates cognitive deficit and inhibits hippocampal inflammatory response and oxidative stress in rats with traumatic brain injury.

Authors:  Wei Zhang; Ben Li; Yan Guo; Yunan Bai; Tongxin Wang; Kun Fu; Gaoling Sun
Journal:  Cent Eur J Immunol       Date:  2015-04-22       Impact factor: 2.085

10.  Altered Blood Biomarker Profiles in Athletes with a History of Repetitive Head Impacts.

Authors:  Alex P Di Battista; Shawn G Rhind; Doug Richards; Nathan Churchill; Andrew J Baker; Michael G Hutchison
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.